Evidence map›Paper›PMID 29490770›Full record

ArticleAllergy and asthma proceedings2018

Oliver J Lawless, Joseph A Bellanti, Milton L Brown, Kathryn Sandberg, Jason G Umans, Li Zhou, Weiqian Chen, Julie Wang, Kan Wang, Song Guo Zheng

Abstract read
In one paragraph

Article in Allergy and asthma proceedings, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 25 citations in OpenAlex.

  1. Methylated CpG ODNs fromInternational journal of molecular sciences · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Treg Cells and Epigenetic Regulation.Advances in experimental medicine and biology · 2021
    Article
  8. Treg-inducing capacity of genomic DNA ofAllergy and asthma proceedings · 2020
    Article
  9. Review
  10. Review
  11. Advances in the clinical and mechanism research of pollen induced seasonal allergic asthma.American journal of clinical and experimental immunology · 2019
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Oliver J LawlessDepartment of Pediatrics, Georgetown University Medical Center, Washington, D.C., USA.
Joseph A BellantiDepartment of Pediatrics, Georgetown University Medical Center, Washington, D.C., USA.
Milton L BrownInova Shar Cancer Institute, Center for Drug Discovery and Development, Fairfax, VA, USA.
Kathryn SandbergGeorgetown-Howard Universities Center for Clinical and Translational Science, Washington, D.C., USA.
Jason G UmansMedStar Health Research Institute, Hyattsville, MD, USA.
Li ZhouDivision of Rheumatology, Milton S. Hershey Medical Center at Penn State University, Hershey PA, USA.
Weiqian ChenDivision of Rheumatology, Milton S. Hershey Medical Center at Penn State University, Hershey PA, USA.
Julie WangDivision of Rheumatology, Milton S. Hershey Medical Center at Penn State University, Hershey PA, USA.
Kan WangInova Shar Cancer Institute, Center for Drug Discovery and Development, Fairfax, VA, USA.
Song Guo ZhengDivision of Rheumatology, Milton S. Hershey Medical Center at Penn State University, Hershey PA, USA.
Penn State Milton S. Hershey Medical Center · USInova Fairfax Hospital · USGeorgetown-Howard Universities Center for Clinical and Translational Science · USGeorgetown University · USGeorgetown University Medical Center · USMedStar Health · US

Funding

Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
Therapeutic immunoregulation mediated by TGF-??-induced iTregs in autoimmune arthR01AR059103 · NIAMS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI JARJOUR, WAEL N · 2010 to 2020
$3.9M
Mesenchymal Stem Cells Derived from Human Gingiva (GMSC) Inhibit Bone Erosion in Autoimmune ArthritisR61AR073049 · NIAMS · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI ZHENG, SONG GUO · 2017 to 2018
$767k
NCATS NIH HHS UL1 TR001409NIAMS NIH HHS R01 AR059103NIAMS NIH HHS R61 AR073049
6 · The paper itself

Abstract

backgroundAllergic and autoimmune diseases comprise a group of inflammatory disorders caused by aberrant immune responses in which CD25+ Forkhead box P3-positive (FOXP3+) T regulatory (Treg) cells that normally suppress inflammatory events are often poorly functioning. This has stimulated an intensive investigative effort to find ways of increasing Tregs as a method of therapy for these conditions. One such line of investigation includes the study of how ligation of Toll-like receptors (TLRs) by CpG oligonucleotides (ODN) results in an immunostimulatory cascade that leads to induction of T-helper (Th) type 1 and Treg-type immune responses.

objectiveThe present study investigated the mechanisms by which calf thymus mammalian double-stranded DNA (CT-DNA) and a synthetic methylated DNA CpG ODN sequence suppress in vitro lymphoproliferative responses to antigens, mitogens, and alloantigens when measured by [3H]-thymidine incorporation and promote FoxP3 expression in human CD4+ T cells in the presence of transforming growth factor (TGF) beta and interleukin-2 (IL-2).

methodsLymphoproliferative responses of peripheral blood mononuclear cells from four healthy subjects or nine subjects with systemic lupus erythematosus to CT-DNA or phytohemagglutinin (PHA) was measured by tritiated thymidine ([3H]-TdR) incorporation expressed as a stimulation index. Mechanisms of immunosuppressive effects of CT-DNA were evaluated by measurement of the degree of inhibition to lymphoproliferative responses to streptokinase-streptodornase, phytohemagglutinin (PHA), concanavalin A (Con A), pokeweed mitogen (PWM), or alloantigens by a Con A suppressor assay. The effects of CpG methylation on induction of FoxP3 expression in human T cells were measured by comparing inhibitory responses of synthetic methylated and nonmethylated 8-mer CpG ODN sequences by using cell sorting, in vitro stimulation, and suppressor assay.

resultsHere, we showed that CT-DNA and a synthetic methylated DNA 8-mer sequence could suppress antigen-, mitogen-, and alloantigen-induced lymphoproliferation in vitro when measured by [3H]-thymidine. The synthetic methylated DNA CpG ODN but not an unmethylated CpG ODN sequence was shown to promote FoxP3 expression in human CD4+ T cells in the presence of TGF beta and IL-2. The induction of FoxP3+ suppressor cells is dose dependent and offers a potential clinical therapeutic application in allergic and autoimmune and inflammatory diseases.

conclusionThe use of this methylated CpG ODN offers a broad clinical application as a novel therapeutic method for Treg induction and, because of its low cost and small size, should facilitate delivery via nasal, respiratory, gastrointestinal routes, and/or by injection, routes of administration important for vaccine delivery to target sites responsible for respiratory, gastrointestinal, and systemic forms of allergic and autoimmune disease.

Indexed as

AnimalsCattleCD4-Positive T-LymphocytesCell ProliferationCells, CulturedCpG IslandsDNADNA MethylationForkhead Transcription FactorsHumansHypersensitivityImmunosuppression TherapyImmunotherapyIsoantigensLupus Erythematosus, SystemicLymphocyte ActivationDNAForkhead Transcription FactorsFOXP3 protein, humanIsoantigensTransforming Growth Factor beta

Identifiers

PMID29490770
PMCPMC6479479
OpenAlexW2794268023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.